Welcome to our dedicated page for Edesa Biotech SEC filings (Ticker: EDSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edesa Biotech filings document the formal disclosure record of a clinical-stage biotechnology issuer focused on host-directed therapeutics for immuno-inflammatory diseases. Recent Form 8-K reports cover clinical-study disclosures for paridiprubart in Acute Respiratory Distress Syndrome, operating and financial results, material-event updates and agreements connected to funded development work.
The company’s filings also address capital-structure matters, including common-share sales under at-the-market offering arrangements and related Form S-3 prospectus supplements. Proxy materials cover shareholder voting matters, board governance, executive compensation and equity-award disclosures for the public company.
Edesa Biotech, Inc. ownership update: Stonepine entities and Jon M. Plexico report beneficial ownership of 30,000 shares of Common Stock, representing 0.3% of the class.
The filing states the percentage is calculated based on 8,891,951 shares outstanding as of May 13, 2026. The reporting persons say the shares were not acquired to influence control and disclaim group membership.
EDESA Biotech filing an Amendment No. 2 to Schedule 13G/A reporting zero beneficial ownership. The filing states that as of 03/31/2026 Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, may be deemed to beneficially own 0 Shares representing 0.00% of the outstanding Common Shares (CUSIP 27966L306).
The filing lists addresses for the issuer and the reporting persons and confirms that Nantahala is a Massachusetts limited liability company and that Harkey and Mack are U.S. citizens. Signatures by the reporting persons and the Chief Compliance Officer appear with a signature date of 05/15/2026.
Edesa Biotech Schedule 13G/A: Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen reported shared voting and dispositive power over 2 Common Shares of Edesa Biotech as of the close of business on March 31, 2026. The filing states the reporting persons directly own no Common Shares and reports 0% of the class.
The statement clarifies organizational relationships: Point72 Capital Advisors is general partner of Point72 Asset Management, Mr. Cohen controls both, and Cubist Systematic Strategies, LLC acts as a sub-adviser for a portion of the shares. Signatures by an authorized person appear dated May 15, 2026.
Edesa Biotech reports a Schedule 13G showing Rubric Capital Management and David Rosen beneficially own 687,500 Common Shares (7.74%). The filing states the holdings reflect 8,885,719 Common Shares outstanding as of March 30, 2026. The reported position is held by Rubric Funds with shared voting and dispositive power of 687,500 shares, and Rubric Long Term Opportunities Offshore Master Fund, LP is identified as having the right to receive dividends or sale proceeds on more than 5% of the class.
Edesa Biotech disclosed that Chief Executive Officer Dr. Pardeep Nijhawan has elected to receive a much larger portion of his compensation in stock-based awards rather than cash. Under his Amended and Restated Employment Agreement, the Board approved that 90% of his monthly base salary will now be paid in the form of fully vested restricted share units (RSUs) granted under the company’s 2019 Equity Incentive Compensation Plan.
The number of RSUs issued each month will be determined by dividing 90% of his monthly base salary by the fair market value of Edesa’s common shares at each month end. The remaining 10% of his salary will continue to be paid in cash to meet local labor law and withholding requirements. Previously, Dr. Nijhawan received 50% of his base salary as RSUs, so this change further aligns his compensation with the company’s share performance.
Edesa Biotech disclosed a 600,000 shares holding by Sirenia Capital/related filer, representing 7.2% of the class. The filing states the percentage is calculated using 8,348,161 Common Shares outstanding as of February 12, 2026.
The statement is a Schedule 13G joint filing by Sirenia Capital Management LP and Alex Silverstein and notes the shares are held by SILV Fund, Ltd.; shared voting and dispositive power of 600,000 shares is reported.
Edesa Biotech, Inc. reported a net loss of $4.2 million for the quarter and $6.5 million for the six months ended March 31, 2026, wider than the prior-year periods. Loss per share was $0.49 for the quarter and $0.78 year-to-date.
Research and development spending rose sharply to $2.8 million for the quarter and $3.9 million year-to-date, driven mainly by manufacturing and preparations for a Phase 2 vitiligo study (EB06) and readiness work for paridiprubart. General and administrative expenses also increased to $1.5 million for the quarter and $2.7 million for six months.
Edesa ended the period with $10.0 million in cash and cash equivalents and working capital of $8.2 million. Management discloses that existing cash, potential ATM share sales and Canadian government reimbursements are not expected to fund operations, including the vitiligo program, through fiscal 2026, creating a material going concern uncertainty and a need for additional financing.
Edesa Biotech reported fiscal second quarter 2026 results with a net loss of $4.2 million, or $0.49 per share, for the three months ended March 31, 2026, compared with a net loss of $1.6 million, or $0.30 per share, a year earlier.
Total operating expenses rose to $4.3 million from $1.6 million, driven mainly by higher research and development spending for EB06 vitiligo trial preparations and regulatory and manufacturing work for paridiprubart, along with increased salaries and professional fees.
For the six-month period, the company recorded a net loss of $6.5 million, or $0.78 per share, versus $3.2 million, or $0.74 per share, in the prior-year period. Edesa ended March 31, 2026 with cash and cash equivalents of $10.0 million and working capital of $8.2 million, while advancing preparations for a Phase 2 EB06 vitiligo study and reporting additional positive Phase 3 data for paridiprubart in Acute Respiratory Distress Syndrome.
Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an equity award and updated share holdings. He received a grant of 1,159 restricted share units that vested in full upon grant at a price of $0.0000 per share under the company’s 2019 Equity Incentive Compensation Plan, increasing his direct holdings to 632,550 common shares following the award.
Indirect holdings are reported through several entities: 402,702 common shares held by Pardeep Nijhawan Medicine Professional Corporation, 53,104 shares held by 1968160 Ontario Inc., 32,013 shares held by The Digestive Health Clinic Inc., and 32,609 shares held by The New Nijhawan Family Trust 2015. The reporting person disclaims beneficial ownership of these indirect securities except to the extent of his pecuniary interest.
Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech, Inc. reported that Chief Executive Officer Pardeep Nijhawan received a grant of 2,578 restricted share units on April 1, 2026, which vested in full upon grant under the 2019 Equity Incentive Compensation Plan. Following this award, he directly holds 631,391 common shares, with additional indirect holdings reported through several affiliated entities and a family trust.